The US Food and Drug Administration (USFDA) has notified that Zydus Pharmaceuticals USA , the US subsidiary of Cadila Healthcare , has voluntarily recalled 19,536 bottles of benzonatate capsules. The drug indicated for the treatment ... 4 Traders, 2 weeks ago
Cadila recalls 19,536 bottles of cough treatment drug in US - Business Standard India, 2 weeks ago
Cadila recalls cough treatment drug in U.S. - The Hindu, 2 weeks ago
1 images for "zydus cadila"
Zydus Cadila announced the launch of its biosimilar Adalimumab, following an approval from the Drug Controller General (India). According to a press release, the biosimilar was developed by researchers at the Zydus Research Centre. To be marketed ...Financial Express, 1 month ago Zydus Cadila launches biosimilar of Humira Bio Spectrum Asia, 1 month ago India firm launches biosimilar for autoimmune disease Bio Spectrum Asia, 1 month ago Cadila launches cheaper copy of Abbvie's Humira Financial Chronicle, 1 month ago
Firstcall Research report on Cadila Healthcare "For the Second quarter ended Sept 30, 2014, Zydus Cadila reported sales of Rs. 21080.00 mn, up by 20.68% from Rs. 17467.90 mn in the corresponding quarter of the previous year on a consolidated ...Moneycontrol.com, 1 month ago Humira biosimilar released in India Pharmafocus, 1 month ago We hope to launch 2 original drugs by 2020: Cadila chairman Pankaj Patel Economic Times, 1 month ago Zydus Cadila Launches Abbvie's Humira Biosimilar in India PharmaAsia, 1 month ago
Corporate majors like Cadila Healthcare Ltd and Torrent Group were among the top donors from Gujarat to have contributed to the election kitty of Indian National Congress (INC) and Nationalist Congress Party (NCP) for the 2014 Lok Sabha elections. ...Hindu Business Line, 1 month ago CADILA HEALTHCARE : Torrent, Cadila among donors to Cong, NCP 4 Traders, 1 month ago Torrent Group & Cadila Healthcare among top political donors from Gujarat during 2013-14 Indian Express, 1 month ago Torrent Group, Cadila Healthcare among top political donors from Gujarat; BJP only defaulter Financial Express, 1 month ago
Ebolavirus under an electron microscope--Courtesy of CDC The latest drugmaker diving into the Ebola vaccine race? India's Zydus Cadila. The pharma is developing jabs for the deadly virus and tick-borne viral Crimean-Congo hemorrhagic fever, The ...FierceVaccines, 2 weeks ago Zydus Cadila developing Ebola, Congo fever vaccines Times of India, 3 weeks ago
Zydus Cadila, which pioneered a breakthrough with Lipaglyn (Saroglitazar) last year, is now studying the effect of this drug on fatty and inflamed liver.Times of India, 1 month ago
g biologics as a critical growth driver for the future, Ahmedabad-based Zydus Cadila is aiming to clock revenues worth Rs 500 crore from the division in the next three to five years. The company today launched the biosimilar of Adalimumab, used for treatment ...Business Standard, 1 month ago
Companies like Intas Pharma, Torrent Pharma, Zydus Cadila etc already have facilities in Sikkim Sohini Das | Ahmedabad November 2, 2014 Last Updated at 20:58 IST Vadodara-based pharma company Alembic Pharmaceuticals is all set to commission its formulations ...Business Standard, 2 months ago Torrent Pharmaceuticals : Pharma inks pact with Reliance for 3 biosimilars 4 Traders, 1 month ago Torrent Pharma inks pact with Reliance for 3 biosimilars [DNA : Daily News & Analysis (India)] Pharmacy Choice, 1 month ago
Zydus Cadila reported a 52 per cent rise in net profit to Rs 278 crore for the second quarter of the 2014-15 fiscal riding on the back of a 21 per cent rise in total operating income. The Ahmedabad-based pharma major posted a total operating income of Rs ...Sify, 2 months ago Cadila Healthcare Q2 net up 52% at Rs 278 crore The Financial Chronicle, 2 months ago
Zydus Cadila, a pharmaceutical company, has initiated Phase III clinical trials to study the effect of Saroglitazar in adult nonalcoholic steatohepatitis, or NASH, patients. The Phase III trial will be of 52 week duration and will study the efficacy ...Individual.com, 2 weeks ago Zydus begins Phase - III study of Saroglitazar in NASH, a liver disease caused by obesity, diabetes and lipid disorders PipelineReview, 2 weeks ago Pieris Initiates Phase I Clinical Trial for Anticalin(R) to Treat Anemia CEOWorld Magazine, 1 month ago
on your WebpageAdd Widget >Get your members hooked!